BIIB122: a LRRK2 Small Molecule Inhibitor for Parkinson’s Disease
Time: 8:45 am
day: Day Two
Details:
- LRRK2 as a target against Parkinson’s Disease
- Reviewing phase I data safety and target engagement
- Evaluating study design approaches for ongoing clinical trials
